Thursday, November 11, 2021

PDS Biotechnology Corp (PDSB)
3Q21 Contained Clinical Progress and New Product Licenses

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

PDS Biotechnology reported 3Q21 loss of $6.9 million or $(0.24) per share, compared with our estimated loss of $6.1 million or $(0.21) per share. The company held a conference call in which it reviewed two licensing agreements announced earlier in November 2021. These products advance the pipeline and broaden the development of products that use the Versamune technology. Cash balance at the end of the quarter was $69.7 million.

PDS0102 Reached A Development Milestone PDS0102 has been in preclinical testing for prostate cancer, breast cancer, and acute myeloid leukemia (AML) using the TARP antigen with the Versamune platform.  Based on its strong results, PDS made a license agreement with the NCI (National Cancer Institute) that gives the company rights to NCI’s intellectual property related to the antigen. The license ...

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.